Trial Profile

A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 16 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary)
Indications Carcinoma; Prostate cancer
Focus Therapeutic Use

Most Recent Events

11 Sep 2024 Results(n=21) discussing association of Immune-enriched transcriptional signatures in pre-treatment tumors with response to ipilimumab in patients with mCRPC , presented at the CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference
07 Jan 2020 Status changed from active, no longer recruiting to completed.
07 Jan 2020 Planned End Date changed from 1 Aug 2020 to 31 Aug 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com